ArticleFrontiers in immunology2026
Nucleo-mitochondrial asymmetry profiles the proliferative engine and spatial niche reconstruction in clear cell renal cell carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor heterogeneity is the key driver of disease progression and therapeutic resistance in clear cell renal cell carcinoma (ccRCC). Within this landscape, mitochondrial (MT) heterogeneity has emerged as a critical but poorly understood feature. This study identified a specific manifestation of MT heterogeneity termed "nucleo-mitochondrial expression asymmetry (NMA)". It is characterized by a dysregulated burst of mitochondrial DNA (mtDNA)-encoded genes compared to the nuclear genome, marking a pivotal tipping point in tumor proliferation and spatial reconstruction. Methods: We employed an integrative multi-omics approach combining single-cell RNA sequencing (scRNA-seq), spatial transcriptomics (stRNA-seq), and mass spectrometry imaging (MSI)-based spatial metabolomics from the Tongji Renal Cell Carcinoma (TJ-RCC) cohort. To identify and characterize the profound NMA malignant subpopulations, we utilized Gaussian Mixture Model (GMM) clustering, CytoTRACE 2 for differentiation potential, and scFEA for metabolic flux inference. We implemented neighborhood and pseudo-spatiotemporal map (pSM) analyses to quantify spatial reconstruction. We validated these findings through mitochondrially encoded cytochrome Results: We identified a unique malignant subpopulation (C0) defined by NMA, where nucleo-mitochondrial coordination significantly decreased to R = 0.30 compared to R = 0.50 in other clusters. C0 functioned as a proliferative engine, exhibiting the highest ribosomal activity, peak differentiation potential, and concentrated G2M/S-phase activity. Metabolic modeling and MSI revealed that C0-dominant regions act as metabolic hubs, correlating with total metabolic flux (R = 0.631) and the physical accumulation of tricarboxylic acid (TCA) cycle intermediates. Spatially, C0 abundance was highly predictive of global MT gene scores (R = 0.852). As ccRCC progressed, NMA-driven niches underwent a dramatic reconstruction: transitioning from an "immune-active core" in the early stages to stroma-shielded "metabolic islands" in the advanced stages. Furthermore, we observed a resurgence of NMA and the C0 subpopulation in metastatic lesions. Clinical validation confirmed that MT-CO1 protein levels-a histological proxy for NMA-positively correlated with the proliferation marker Ki67 (r = 0.702) and served as an independent prognostic factor for overall survival. Conclusion: This study characterized NMA as a hallmark of ccRCC progression and spatial niche reconstruction, offering a novel, clinically actionable framework for metabolic risk stratification via MT-CO1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.